Cancer Treat Rev. The epidermal growth factor receptor (EGFR) is implicated in various malignancies. Clinicopathological features of cancer patients with glomerular diseases associated with EGFR inhibitor use. FDA approved (2007, metastatic breast cancer), Phase II (metastatic gastric, cholangiocarcinoma), Third-generation/mutant-selective EGFR TKIs,